INCA-6

INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the ?calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling^[1][2][3]. In Vitro: INCA-6 (5 μM; for 24-hour) prevents?transient outward K+?current (Ito)?downregulation in 3-Hz cells^[1].
Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia^[2].?
INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of ?thapsigargin (TG)^[3].
INCA-6 (1.0 and 2.5 μM; 24 hours?) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation^[4]. In Vivo: INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)^[4].